Abstract
The aim of the study was to investigate IL-33 expression in gastric cancer (GC) and its association with the clinical characteristics and the prognosis. IL-33 protein in tumor and corresponding adjacent tissues were detected by immunohistochemistry in 179 GC patients and clinical features plus prognostic value were analyzed via Pearson’s chi-square test and Kaplan–Meier test in Cox proportional hazards model, respectively. IL-33 protein levels were significantly lower in tumor tissues than adjacent tissues (29.05% vs. 78.77%, χ 2 = 89.05, P < 0.001). The positive rate of IL-33 in the ulcerative type group was the lowest among all groups (P < 0.05). IL-33 levels were correlated with age (P = 0.025) and invasion depth (P = 0.030) while not significantly associated with the overall survival of GC patients. IL-33 expression is associated with age and invasive depth of GC patients but not an independent risk factor of prognosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen W, Zheng R, Zeng H, Zhang S, He J (2015) Annual report on status of cancer in China, 2011. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 27(1):2–12. doi:10.3978/j.issn.1000-9604.2015.01.06
Dinarello CA (1994) The biological properties of interleukin-1. Eur Cytokine Netw 5(6):517–531
Klemenz R, Hoffmann S, Werenskiold AK (1989) Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci U S A 86(15):5708–5712
Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M (1994) Alternative promoter usage of the Fos-responsive gene fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 13(5):1176–1188
Verri WA Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, Ferreira SH, Liew FY, Cunha FQ (2008) IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 105(7):2723–2728. doi:10.1073/pnas.0712116105
Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, Lu J, Qin W, Qi Y, Xie F, Jiang J, Wu C, Zhang X, Chen X, Turnquist H, Zhu Y, Lu B (2015) Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol 194(1):438–445. doi:10.4049/jimmunol.1401344
Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y (2011) Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56(12):3596–3601. doi:10.1007/s10620-011-1760-5
XX Y, Hu Z, Shen X, Dong LY, Zhou WZ, WH H (2015) IL-33 promotes gastric cancer cell invasion and migration via ST2-ERK1/2 pathway. Dig Dis Sci 60(5):1265–1272. doi:10.1007/s10620-014-3463-1
Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu Y, Yang H, Chen D, Wang S, Xu H (2014) Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res 2014:923135. doi:10.1155/2014/923135
Moussion C, Ortega N, Girard JP (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3(10):e3331. doi:10.1371/journal.pone.0003331
Bergis D, Kassis V, Ranglack A, Koeberle V, Piiper A, Kronenberger B, Zeuzem S, Waidmann O, Radeke HH (2013) High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 6(3):311–318
Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML (2014) Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. International Journal of Cancer Journal International Du Cancer 134(7):1669–1682. doi:10.1002/ijc.28481
Brunner SM, Rubner C, Kesselring R, Martin M, Griesshammer E, Ruemmele P, Stempfl T, Teufel A, Schlitt HJ, Fichtner-Feigl S (2015) Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61(6):1957–1967. doi:10.1002/hep.27728
Deng K, Wang H, Shan T, Chen Y, Zhou H, Zhao Q, Xia J (2016) Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci Rep 6:24505. doi:10.1038/srep24505
Bergis D, Kassis V, Radeke HH (2016) High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomarkers : Section a of Disease Markers 16(1):117–125. doi:10.3233/CBM-150547
Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN, Shao JP, Ji H (2015) IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep 33(6):2746–2752. doi:10.3892/or.2015.3898
Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK (2005) Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol 11(1):22–26
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Drs. Wenwei Hu and Xiaodong Li are the co-first authors
Rights and permissions
About this article
Cite this article
Hu, W., Li, X., Li, Q. et al. Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. Pathol. Oncol. Res. 23, 615–619 (2017). https://doi.org/10.1007/s12253-016-0167-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-016-0167-1